Literature DB >> 15065218

Electron microscopic dual labeling of high-affinity neurotensin and dopamine D2 receptors in the rat nucleus accumbens shell.

Karen T Delle Donne1, June Chan, Helene Boudin, Didier Pélaprat, William Rostène, Virginia M Pickel.   

Abstract

The dopamine D2 receptor (D2R) in the nucleus accumbens (NAc) shell is implicated in schizophrenia and in psychostimulant-induced drug-seeking behavior, both of which are affected by activation of the functionally opposed high-affinity neurotensin receptor (NTS1). To determine the functionally relevant sites, we examined the dual electron microscopic immunocytochemical localization of D2R and NTS1 in the NAc shell of rat brain. Immunolabeling for each receptor was seen in association with cytoplasmic organelles, or more rarely, on the plasma membrane of both axonal and somatodendritic profiles. Some of the axonal and many of the dendritic processes colocalized the two receptors. The dually labeled axon terminals often formed symmetric synapses or appositional contacts with unlabeled dendritic profiles. The morphology of these terminals suggests that they contain either inhibitory amino acids or dopamine. Other axonal profiles expressing exclusively NTS1 or D2R were without synaptic specializations or formed asymmetric, excitatory-type synapses mainly on unlabeled dendritic spines. In addition, however, several D2R-immunoreactive terminals were observed presynaptic to dendrites containing NTS1. The somatodendritic profiles immunolabeled for NTS1 and/or D2R had morphological features typical of inhibitory spiny projection neurons in the NAc. These results suggest that activation of NTS1 and D2R can dually modulate transmitter release from the same or separate phenotypically distinct axon terminals in the NAc shell. These presynaptic receptors as well as the postsynaptic NTS1 distribution in neurons that also contain or receive input from terminals containing D2R may mediate the opposing actions of neurotensin and dopamine in the NAc. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15065218     DOI: 10.1002/syn.20018

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  7 in total

1.  Neurotensin reduces glutamatergic transmission in the dorsolateral striatum via retrograde endocannabinoid signaling.

Authors:  Henry H Yin; Louise Adermark; David M Lovinger
Journal:  Neuropharmacology       Date:  2007-06-22       Impact factor: 5.250

2.  Hyperactivity of the dopaminergic system in NTS1 and NTS2 null mice.

Authors:  Yanqi Liang; Mona Boules; Zhimin Li; Katrina Williams; Tomofumi Miura; Alfredo Oliveros; Elliott Richelson
Journal:  Neuropharmacology       Date:  2010-03-06       Impact factor: 5.250

Review 3.  Neurotensin in reward processes.

Authors:  María Luisa Torruella-Suárez; Zoe A McElligott
Journal:  Neuropharmacology       Date:  2020-02-11       Impact factor: 5.250

4.  Association between neurotensin receptor 1 gene polymorphisms and alcohol dependence in a male Han Chinese population.

Authors:  Hui Ma; Yinglin Huang; Bo Zhang; Yuan Wang; Hong Zhao; Hong Du; Zhengtu Cong; Jingying Li; Gang Zhu
Journal:  J Mol Neurosci       Date:  2013-06-08       Impact factor: 3.444

5.  Ketamine induces dopamine-dependent depression of evoked hippocampal activity in the nucleus accumbens in freely moving rats.

Authors:  Mark J Hunt; Karima Kessal; Rene Garcia
Journal:  J Neurosci       Date:  2005-01-12       Impact factor: 6.167

6.  Dendritic distributions of dopamine D1 receptors in the rat nucleus accumbens are synergistically affected by startle-evoking auditory stimulation and apomorphine.

Authors:  Y Hara; V M Pickel
Journal:  Neuroscience       Date:  2007-05-09       Impact factor: 3.590

7.  Mu-opioid and corticotropin-releasing-factor receptors show largely postsynaptic co-expression, and separate presynaptic distributions, in the mouse central amygdala and bed nucleus of the stria terminalis.

Authors:  A Jaferi; V M Pickel
Journal:  Neuroscience       Date:  2009-01-08       Impact factor: 3.590

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.